chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, SARS-CoV-2 test
Clinical narrative: Cold symptoms; Loss of smell; More than usual clots during monthly period; Sore arm; Headache; Fatigue; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the right arm on 22Apr2021 at 17:45 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to fresh mint leaf. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the right arm on 31Mar2021 at 18:30 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. The patient previously received codeine on an unknown date and experienced drug allergy. On 28Apr2021, the patient experienced sore arm, cold symptoms, loss of smell, headache, fatigue, and had more than usual clots during monthly period. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had been tested for COVID-19. The patient underwent rapid test via nasal swab on 01May2021 and the result was negative. Therapeutic measures were taken as a result of the events and included treatment with TYLENOL and Ibuprofen. The clinical outcome of the events sore arm, cold symptoms, loss of smell, headache, fatigue, and more than usual clots during monthly period were not recovered at the time of report.   No follow-up attempts are possible. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain, Pyrexia, Vaccination site swelling
Clinical narrative: Body aches; Low grade fever; nausea; swelling at shot site; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 30Apr2021 at 08:00 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. Medical history included restless leg syndrome. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously took prochlorperazine edisylate (COMPAZINE) on an unspecified date for an unknown indication and experienced drug allergy. Concomitant medications included ropinirole hydrochloride (ROPINIROLE) and chondroitin, glucosamine (CHONDROITIN; GLUCOSAMINE) on an unknown date for unknown indication. The patient also previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 09Apr2021 at 08:00 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01May2021 at 02:00 the patient experienced body aches, low grade fever, nausea, swelling at shot site. No therapeutic measures were taken as a result of event. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event body aches, low grade fever, nausea, swelling at shot site was not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Sex: U
Vaccine: COVID19
Symptoms: Myalgia
Clinical narrative: Intense muscle pain, left butt.; This is a spontaneous report from a contactable consumer, the patient. An elderly patient of unknown gender received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 17Mar2021, as a single dose for COVID-19 immunisation. Medical history included high Blood Pressure (BP) and cholesterol which were under control. The patient had no allergies to medications, food, or other products. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN), levothyroxine (MANUFACTURER UNKNOWN), lisinopril (MANUFACTURER UNKNOWN) and omeprazole (MANUFACTURER UNKNOWN). The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3246) via an unspecified route of administration in the left arm on an unknown date in 2021, as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Mar2021, the patient experienced intense muscle pain in left butt for 3 days. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event intense muscle pain in the left butt was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Fatigue, SARS-CoV-2 test, Tongue discomfort, Tongue ulceration
Clinical narrative: It feels like have a metallic taste on and off; the sides of my tongue feel ulcerated, but my tongue looks normal; I have also felt fatigued ever since my second shot; I have been having ongoing burning tongue syndrome; This is a spontaneous report from a contactable nurse, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL1284) via an unspecified route of administration in the right arm on 13Jan2021 at 08:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included hearing impaired and anxiety. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included clonazepam (MANUFACTURER UNKNOWN), amfetamine aspartate; amfetamine sulfate; dexamfetamine saccharate; dexamfetamine sulfate (ADDERALL), ascorbic acid (VITAMIN C), vitamin d nos (MANUFACTURER UNKNOWN) and zinc (MANUFACTURER UNKNOWN), all for unknown indications from unknown dates and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EH9899) via an unspecified route of administration in the left arm on 23Dec2020 at 12:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. On 13Jan2021 at 13:00, since the second shot about 5 hours after, the patient had been having ongoing burning tongue syndrome. It felt like had a metallic taste on and off. Also the sides of the tongue felt ulcerated, but the tongue looked normal. The patient had also felt fatigued ever since she got the second shot. The events resulted in doctor or other healthcare professional office/clinic visit and the patient had seen her primary care physician (PCP), ENT and Periodontist. Therapeutic measures were taken as a result of reported events and included treatment with Nystatin, metronidazole, omeprazole and acyclovir. Since the vaccination, the patient had been tested for COVID-19. On 19Apr2021, the patient underwent lab tests and procedures which included PCR test for COVID-19 (Nasal swab) and tested negative. The clinical outcome of the events ongoing burning tongue syndrome, metallic taste on and off, sides of the tongue feel ulcerated and felt fatigued was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Rash macular, Rash pruritic
Clinical narrative: Several itchy circles on body, some dime sized, some larger and all have a red outline.; Several itchy circles on body, some dime sized, some larger and all have a red outline.; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm on  08Apr2021 at 10:30 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history of the patient was not reported. The patient had no known allergies to medications, food and other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within 2 weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER872) via an unspecified route of administration in the left arm on an unknown date  as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01May2021 at 08:00, the patient experienced several itchy circles on body, some dime sized, some larger and all have a red outline.  No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events several itchy circles on body, some dime sized, some larger and all have a red outline was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Nausea, Pain, Pyrexia, SARS-CoV-2 test, Vomiting
Clinical narrative: Fever; Nausea; Vomiting; Body aches; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 30Apr2021 at 14:00 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medication included cetirizine hydrochloride (ZYRTEC) from an unknown date for an unspecified indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 09Apr2021 at 14:00 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. On 01May2021 at 03:00, the patient experienced fever, nausea, vomiting, body aches. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. On an unknown date in 2021, the patient underwent SARS-CoV-2 test (Nasal swab) and the result was negative. The clinical outcome of the events fever, nausea, vomiting, body aches was not recovered.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Sex: M
Vaccine: COVID19
Symptoms: Hypoaesthesia
Clinical narrative: Numbness in his left hand that ran up his left arm to the vaccine area where the shot was administered.; This is a spontaneous report from a contactable consumer. A male patient of an unknown age received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 29Apr2021 as a single dose for COVID-19 immunisation. Patients medical history and concomitant medications were unknown. Allergies were unknown. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. It was unknown if the patient received any other vaccines within four weeks prior to the COVID-19 vaccine. On 29Apr2021, the patient experienced numbness in his left hand that ran up his left arm to the vaccine area where the shot was administered. He said that he was willing to speak to Pfizer if they wanted to contact him. The event resulted in emergency room/department or urgent care. It was unknown whether any therapeutic measures were taken as a result of the events. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. The clinical outcome of the events numbness in his left hand that ran up his left arm to the vaccine area where the shot was administered was recovered with sequelae.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, Rash, Rash pruritic, SARS-CoV-2 test
Clinical narrative: Full body rash with dark purple, itchy bumps; Whole body rash; Fever; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 21Apr2021 at 17:30 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included somewhat high blood pressure, high cholesterol, gout, penicillin allergy, cat allergy and seasonal allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included allopurinol (MANUFACTURER UNKNOWN) and atorvastatin (MANUFACTURER UNKNOWN) from unknown dates for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration on 31Mar2021 at 17:30 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. On 21Apr2021, the night of the second shot, the patient broke out in a whole body rash, and got better after about 3 days. The patient then got a fever that lasted for about 4-5 days and on an unknown date the patient experienced full body rash with dark purple, itchy bumps. The patient no longer had fever. The events resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  Since the vaccination, the patient had been tested for COVID-19. On 30Apr2021, the patient underwent COVID-19 test via nasal swab and the result was negative. Therapeutic measures were taken as a result of events whole body rash and full body rash with dark purple, itchy bumps and included treatment with prednisone (MANUFACTURER UNKNOWN) and hydroxyzine (MANUFACTURER UNKNOWN). The clinical outcome of the event fever was recovered on an unknown date in Apr2021 while that of whole body rash and full rash with dark purple, itchy bumps were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Hyperhidrosis, Tremor
Clinical narrative: Sweating; slight trembles; This is a spontaneous report from a contactable consumer, the patient. A 34-years-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 01May2021 at 09:00 (at the age of 34-years-old) as a single dose for COVID-19 immunisation.  Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. The patient did not take any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 10Apr2021 at 09:00 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01May2021 at 10:00, the patient experienced sweating and slight trembles. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. It was unknown if the patient received any treatment for the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event sweating and slight trembles was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Pain in extremity, SARS-CoV-2 test, Vomiting
Clinical narrative: This is a spontaneous report from a contactable consumer (patient). A 42-year-old male patient received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# ER8738), at the age of 42, via an unspecified route of administration, left arm, on Apr 25, 2021, at 19:30, single dose, for COVID-19 immunisation. Medical history included diabetes and high blood pressure. Concomitant medications included diabetes medications. Prior to the vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient has tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On Apr 26, 2021, at 00:00, patient's left arm hurt. He experienced fatigue and throwing-up. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures taken as a result of the events. On an unknown date, patient underwent COVID-19 test (nasal swab), and the result was negative. The outcome of left arm hurting, fatigue and throwing-up resolved on an unknown date in 2021. No follow-up attempts needed. No further information expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Eye discharge, Eye pain, Eye swelling
Clinical narrative: Swollen eyes; Eye pain with discharge; Eye pain with discharge; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 29Apr2021 at 16:15 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history included severe allergies, anaphylactic, asthma, COVID-19 and allergies to tree nuts, bees. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medication was not reported. The patient previously took codeine (MANUFACTURER UNKNOWN), LEVAQUIN and experienced drug allergy. On 29Apr2021 at 18:00, the patient experienced swollen eyes, and eye pain with discharge. The patient did not receive any treatment for the events. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of swollen eyes, and eye pain with discharge were ongoing at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 16.0
Sex: M
Vaccine: COVID19
Symptoms: Axillary pain, Lymphadenopathy, Swelling
Clinical narrative: Right shoulder after the 2nd shot started to swell up.; Arm pit is much more full and feels very sore.; Lymph nodes are swollen.; This is a spontaneous report from a contactable consumer, the patient. A 16-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the right arm on 08Apr2021 at 14:00 (at the age of 16-years-old) as a single dose for COVID-19 immunisation. The patients' medical history included a known allergy to fentanyl (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medication within two weeks of the COVID-19 vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the right arm an unknown date as a single dose for COVID-19 immunisation. On 30Apr2021 at 12:00, the patient reported that his right shoulder started to swell up after the second dose, the arm pit was much fuller and felt very sore. The patients' father who was a medical professional said that the lymph nodes were swollen. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. It was unknown whether any therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events right shoulder started to swell up, arm pit was much fuller and felt very sore and lymph nodes were swollen were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Influenza like illness
Clinical narrative: Flu-like Muscle Aches; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: CR8735) via an unspecified route of administration in the left arm on 21Apr2021 at 14:15 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis. The patient had no known allergies to medications, food, or other products. The patient had received other medications (not specified) within two weeks of vaccination. The patient previously took the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 31Mar2021 at 10:15 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021 at 18:00, the patient experienced flu-like muscle aches. No therapeutic measures were taken as a result of the event. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event flu-like muscle aches was resolved on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site swelling
Clinical narrative: Injection site swelling; Injection site redness; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0175) via an unspecified route of administration in the left arm on 28Apr2021 at 14:45 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included atrial fibrillation (Afib). Concomitant medications included apixaban (ELIQUIS), diltiazem extended release (MANUFACTURER UNKNOWN), folic acid (MANUFACTURER UNKNOWN) and s (unspecified medication). The patient previously took meloxicam (MANUFACTURER UNKNOWN) and experienced allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the left arm on 05Apr2021 at 14:45 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Apr2021 at 16:00, the patient experienced injection site swelling and redness. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events injection site swelling and redness were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Oral herpes
Clinical narrative: Herpes on mouth; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO0158) via an unspecified route of administration in the left arm on 19Apr2021 at 14:15 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 29Mar2021 at 14:00 (at the age of 51-year-old) as a single dose for COVID-19 immunisation. On 01May2021 at 03:00, the patient experienced herpes on mouth. The event did not result in doctors or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event herpes on mouth was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Lethargy
Clinical narrative: Severe diarrhea; Chills; Lethargy; This is a spontaneous report from a contactable consumer (patient) reporting for herself.  A 34-year-old female non-pregnant patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Batch/Lot Number: ER 8736), dose 2 via an unspecified route of administration, administered in Arm Left on 30Apr2021 at 08:30 (at the age of 34-years-old) as DOSE 2, SINGLE for covid-19 immunisation at Hospital. The patient medical history included, depression, anxiety, chronic insomnia and attention deficit hyperactivity disorder all from an unknown date and unknown if ongoing. Concomitant medications in two weeks included escitalopram oxalate (LEXAPRO), 20mg once a day and methylphenidate hydrochloride (CONCERTA) 36mg once a day both were taken for an unspecified indication, start and stop date were not reported. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Batch/Lot Number: EW 0158), dose 1 via an unspecified route of administration, administered in Arm Left 09Apr2021 at 08:00 AM as a DOSE 1, SINGLE for covid-19 immunisation at Hospital. Other vaccine received in four weeks was none. Patient did not have covid prior vaccination and was not tested for covid post vaccination. On 30Apr2021 at 11:00, the patient experienced severe diarrhea, chills, lethargy. Patient did not receive any treatment for the event. Outcome of all the events were recovering.  No follow-up attempts are possible. No further information is expected.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Abnormal dreams, Burning sensation, Headache
Clinical narrative: Mild headache the next day; Both armpits burning after approximately 20min after getting vaccine then went away about an hour later.; Vivid dreams; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0176) via an unspecified route of administration in the left arm on 30Apr2021 at 15:15 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included 4 titanium rods and 20 titanium screws implanted throughout the body. Concomitant medication included fluticasone propionate, salmeterol xinafoate (WIXELA INHUB); taken for unknown indication from an unknown date and unknown if ongoing. The patient previously received clavulanate potassium; amoxicillin trihydrate (AMOXICLAV) taken for unknown indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Apr2021, the patient experienced both armpits burning after approximately 20 minutes after getting vaccine then went away about an hour later and also experienced vivid dreams. On 01May2021, the next day, the patient had mild headache. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event both armpits burning after approximately 20 minutes after getting vaccine then went away about an hour later was recovered on 30Apr2021. The clinical outcome of the events vivid dreams and mild headache were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Gastritis, Migraine
Clinical narrative: Onset of gastritis within 1 day of receiving 2nd dose of vaccine; Migraine; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration on the left arm on 28Apr2021 at 13:45(at the age of 23-years-old) as a single dose for COVID-19 immunisation. Medical history included GERD, migraine, depression and anxiety.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included rizatriptan (MANUFACTURER UNKNOWN), sertraline (MANUFACTURER UNKNOWN), vitamin d nos (VITAMIN D) and vitamin b complex (MANUFACTURER UNKNOWN). The patient previously took doxycycline (MANUFACTURER UNKNOWN) on an unspecified date for an unknown indication and experienced drug allergy. The patient previously took BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration on the left arm on 07Apr2021 at 12:45 as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Apr2021 at 13:00 the patient experienced onset of gastritis within 1 day of receiving 2nd dose of vaccine as well as 4 migraines from 04/28/21 to 05/01/21. The patient had a history of gastritis and migraines but she not had an episode of gastritis since 2019 and her migraines were usually not this frequent. The patient went to an urgent care walk in clinic on 04/29/21 for gastritis and received a GI cocktail for her symptoms. She was now recovering and treating gastritis with anti acids along with an adjusted diet for GERD and taking her usually prescribed medicine for migraines (rizatriptan 10mg) as needed. She was not sure if it was related to the vaccine but she thought that she should report it anyway. The event resulted in doctor or other healthcare professional office/clinic visit and also in emergency room/department or urgent care. Therapeutic measures were taken as a result of gastritis and migraine and included treatment with GI cocktail and continued use of migraine medicine (rizatriptan 10mg). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event onset of gastritis within 1 day of receiving 2nd dose of vaccine and migraine was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity, Purulent discharge, Vaccination site discharge, Vaccination site pain
Clinical narrative: Left arm was sore at injection point; Pus and discharge at injection site; Pus and discharge at injection site; Could not raise arm without pain; This is a spontaneous report from a contactable consumer, the patient. A 73-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the left arm on 03Mar2021 at 00:00 (at the age of 73-years-old) as a single dose for COVID-19 immunization. Medical history included cancer and diabetes. Concomitant medications were not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19.The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Mar2021, the patient underwent COVID-19 test (nasal swab) and the result was negative. On 03Apr2021 at 00:00, the patient experienced left arm soreness at injection point, pus and discharge at injection site and the patient could not raise arm without pain for 4 weeks and he had pain while raising arm at the time of this report. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events left arm soreness, pus and discharge at injection site and included treatment with cephalexin 500mg for 5 days. The clinical outcome of the events left arm soreness, pus and discharge at injection site and could not raise arm due to pain were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Feeling abnormal, Heart rate, Heart rate increased
Clinical narrative: Elevated heart rate when sitting (sustained 120-125 bpm for a period lasting over 10 minutes); Chills; General feeling under the weather; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 30Apr2021 at 12:45 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included the patient was allergic to iodine dye. The patient did not receive any concomitant medications within two weeks prior to the vaccination.  The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 09Apr2021 at 15:30 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01May2021 at 10:00, the patient experienced elevated heart rate when sitting (sustained 120-125 bpm for a period lasting over 10 minutes), chills and general feeling under the weather. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event elevated heart rate when sitting (sustained 120-125 bpm for a period lasting over 10 minutes), chills and general feeling under the weather were unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Got shingles 4 days after second dose; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0189) via an unspecified route of administration in the left arm on 20Apr2021 at 10:30 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 30Mar2021 at 10:45 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. On 25Apr2021 at 13:15, 4 days after second dose, the patient experienced shingles. Since the vaccination, the patient had not been tested for COVID-19. The event resulted in emergency room/department visit or urgent care. Therapeutic measures were taken as a result of reported event which included treatment with valaciclovir hydrochloride (VALTREX). The clinical outcome of event shingles was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected. .
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Paraesthesia
Clinical narrative: Tingling and numbness of face, hands, feet; Tingling and numbness of face, hands, feet; This is a spontaneous report from a non-contactable consumer, the patient. A 28-year-old female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. On an unknown date, the patient experienced tingling and numbness of face, hands, feet. Since the vaccination, the patient had not been tested for COVID-19. The events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. It was unknown whether any therapeutic measures were taken as a result of the events. The clinical outcomes of the event tingling and numbness of face, hands and feet were not recovered at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Heart rate irregular, Palpitations
Clinical narrative: Heart palpitations; Irregular pulse; This is a spontaneous report from a contactable healthcare professional, the patient. A 63-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 17Mar2021 at 13:30 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were reported as none. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200) via an unspecified route of administration in the left arm on 24Feb2021 at 13:30 as a single dose for COVID-19 immunisation. On 16Apr2021, 4 weeks after second dose, the patient began to experience heart palpitations with irregular pulse. These increased to almost constant and then subsided over the course of 8 days, and they were completely gone at the time of this report and were asymptomatic, no trouble breathing, chest pain, nausea, or weakness. The patient was able to continue with normal fairly active lifestyle. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events heart palpitations and irregular pulse was recovered on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus.; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the arm left on 10Apr2021 at 13:30(at the age of 35-year-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 26Apr2021, the patient experienced tinnitus. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event tinnitus was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Somnolence
Clinical narrative: sleepy for one day.; This is a spontaneous report from a non-contactable consumer. A female patient of unknown age received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. On an unknown date in 2021, the patient experienced sleepy for one day. No therapeutic measures were taken as a result of the reported event. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. The clinical outcome of the event sleepy for one day was recovered on an unknown date in 2021.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Headache, Pain in extremity
Clinical narrative: headache; sore arm; This is a spontaneous report from a non-contactable consumer. A female patient of unknown age received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. On an unknown date in 2021 the patient experienced headache and sore arm. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events headache and sore arm were recovered on an unknown date in 2021   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Blepharospasm
Clinical narrative: Right eyelid twitches; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the left arm on 27Apr2021 at 12:15 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. The patient had no known allergies to medications, food or other products. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 06Apr2021 at 12:15 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27Apr2021, at 17:00 the patient experienced right eyelid twitches. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event right eyelid twitches was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Pyrexia, Vaccination site pain
Clinical narrative: Fever up to 102.5 F; Chills; Fatigue; Intense pain at injection site; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FB-ER8735) via an unspecified route of administration in the left arm on 29Apr2021 at 13:30 (at the age of 27-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Patient had known allergies to egg and tree nuts. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COCID vaccine. The patient previously took the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FB-EW0151) via an unspecified route of administration in the left arm on 08Apr2021 at 09:30 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. On 30Apr2021 at 01:00, the patient experienced fever up to 102.5 F (Degrees Fahrenheit), chills, fatigue and intense pain at injection site. Therapeutic measures were taken as a result of fever up to 102.5 F, chills, fatigue and intense pain at injection site and included treatment with OTC acetaminophen, ibuprofen. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever up to 102.5 F (Degrees Fahrenheit), chills, fatigue and intense pain at injection site were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.